Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 97-106

  Karle, Peter ^a   Müller, Petra ^b,c   Renz, Renate ^b   Jesnowski, Ralf ^c   Saller, Robert ^b   Von Rombs, Kerstin ^b   Nizze, Horst ^c   Liebe, Stefan ^c   Günzburg, Walter H ^a   Salmons, Brian ^b   Löhr, Matthias ^c  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b Bavarian Nordic GmbH   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACROLEIN; CELLULOSE SULFATE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; IFOSFAMIDE; MESNA; OXAZAPHOSPHORINE DERIVATIVE; PHOSPHORAMIDE MUSTARD; RESORUFIN;

ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DRUG TARGETING; ENCAPSULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0031785110     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_16     Document Type: Article

References (28)

1. Ahlgren JD ( 1996): Chemotherapy for pancreatic carcinoma. Cancer; 78: 654-663.
2. Brock N, Hilgard P, Peukert M, Pohl J and Sindermann H (1988): Basis and New developments in the Field of Oxazaphosphorines. Cancer Investigation; 6: 513-532.
3. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, Blatter J (1996): Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer; 73: 101-105.
4. Chen L and Waxman J (1995): Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Research; 55: 581-589.
5. Crandell RA, Fabricant CG, Nelson-Rees WA (1973): Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK). In Vitro; 9: 176-185.
6. Connors TA (1995): The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Therapy; 2: 702-709.
7. Cosset FL, Takeuchi Y, Battini JL, Weiss RA and Collins MK (1995): High-tiler packaging cells producing recombinant retroviruses resistant to human serum. J Virol; 69: 7430-7436.
8. Dirven HAAM, van Ommen B, van Blaederen PJ (1996): Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol; 9: 351-360.
9. Donato MT, Gomez-Lechon MJ, Castell JV (1993): A microassay for measuring cytochrome P4501A1 and P450IIB1 activities in intact human rat hepatocytes cultured on 96-well plates. Anal Biochem; 213: 29-33.
10. Günzburg WH, Karle P, Mrochen S, Sparmann G, Saller R, Klein D, Uckert W and Salmons B (1997): Regulated gene expression after retroviral vector-mediated delivery of cancer-relevant therapeutic genes. Recent Results Cancer Res; 144: 116-126.
11. Kalthoff H, Löhr M, Roeder C, Schmiegel W (1995): Das Pankreaskarzinom: Zellbiologie, Matrixproteine und Wachstumsregulation. In: Erkrankungen des exkretorischen Pankreas; Adler G, Fölsch UR, Mössner J, Singer MV. eds. Fischer, Jena: 2nd edition, p.385-404.
12. Kedzie KM, Balfour CA, Escobar GY, Grimm SW, He YA, Pepperl DJ, Regan JW, Stevens JC, Halpert JR (1991): Molecular basis fora functionally unique cytochrome P450IIB1 variant. J Biol Chem; 266: 22515-22521.
13. Keizer HJ, Ouwerkerk J, Welvaart K, van der Velde CJH, Cleton FJ (1995): Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol; 121: 297-302.
14. Kurowski V, Wagner T (1993): Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloracetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol; 33: 36-42.
15. Löhr M, Trautmann B, Göttler M, Peters S, Zauner I, Maillet B, Klöppel G (1994): Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer; 69: 144-151.
16. Löhr M, Trautmann B, Peters S, Zauner I, Liebe S, Klöppel G, Kreuser ED (1995): Expression and function of integrins in human pancreatic adenocarcinoma. Pancreas; 12: 248-259.
17. Löhr M 1996: Zell- und Molekularbiologie der Bindegewebsreaktion bei Pankreatitis und Pankreaskarzinom. Solvay, Hannover.
18. Löhr M, Müller P, Karle P, Stange J, Mitzner S, Nizze H, Liebe S, Salmons B, Günzburg WH (1997): Targeted chemotherapy by encapsulating cells engineered to deliver CYP2B1, an ifosfamide activating cytochrome P450 gene. Gene Therapy; submitted:
19. McClane SJ, Hamilton TE, DeMatteo RP, Burke C and Raper SE(1997): Effect of adenoviral early genes and the host immune system on in vivo pancreatic gene transfer in the mouse. Pancreas; 15: 236-245.
20. Pear WS, Nolan GP, Scott ML, Baltimore D (1993): Production of high-tiler helper-free retroviruses by transient transfection. Proc Natl Acad Sci (USA); 90: 8392-8396.
21. Reyes G, Villanueva A, Garciá C, Sancho FJ, Piulats J, Lluis F, Capellá G (1996): Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res; 56: 5713-5719.
22. Rosewicz S, Wiedenmann B (1997): Pancreatic carcinoma. Lancet; 349: 485-489.
23. Saller RM, Stange J, Mitzner S, Heinzmann U, Salmons B, Günzburg WH (1997): Encapsulated cells producing retroviral vectors for in vivo gene therapy. Submitted.
24. Stange J, Mitzner S, Dautzenberg H, Ramlow W, Knippel M, Steiner M, Ernst B, Schmidt R, Klinkmann H (1993): Prolonged biochemical and morphological stability of encapsulated liver cells - a new method. Biomat Art Cells & Immob Biotech; 21: 343-352.
25. Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, Collins MK (1996): Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature; 379: 85-88.
26. WHO (1979): WHO handbook for reporting results of cancer treatment. WHO, Geneva.
27. Wright J, Tretyakov O, Ayash L, Elias A, Rosowsky A and Frei EI (1995): Analysis of 4-hydroxycyclophosphamide in human blood. Analyt Biochem; 224: 154-158.
28. Zheng JJ, Chan KK, Muggia F (1994): Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemother Pharmacol; 33: 391-398.